Claudia S.
- Country
- Germany
- Department
- Medizinische Klinik II
Research Overview
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephropathy at High Risk of Progression
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Povetacicept in Adults with Immunoglobulin A Nephropathy
- Evaluation of Ravulizumab Efficacy and Safety in Adult Patients with Immunoglobulin A Nephropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 45 of 194 partner sites.
Specializations
Nephrology Specialization
The investigator demonstrates focused expertise in Immunoglobulin A Nephropathy (IgAN), conducting research to advance therapeutic approaches for this kidney condition.
- Kidney Function Preservation
- Proteinuria Management
- Renal Function Assessment
Their research explores novel therapeutic agents targeting IgAN pathways and mechanisms.
Therapeutic Innovation
The investigator evaluates cutting-edge treatments including complement inhibitors and novel biological therapies for kidney disorders.
- Targeted Therapies
- Biological Treatments
- Disease Modification
Their work encompasses the assessment of innovative therapeutic approaches for glomerular diseases.
Clinical Outcomes
The investigator focuses on measuring and improving key renal health indicators in IgAN patients.
- Kidney Function Markers
- Disease Progression
- Treatment Response
Their research evaluates therapeutic efficacy through established renal function parameters.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.